|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.05.26 - 14:06
|
Timothy P. Walbert Joins Patient Square Capital as a Senior Advisor (Business Wire)
|
|
|
MENLO PARK, Calif.--(BUSINESS WIRE)--Patient Square Capital, a leading health care investment firm, today announced that Timothy P. Walbert has joined the firm as a Senior Advisor.
Mr. Walbert brings more than three decades of biopharmaceutical leadership experience and currently serves as Managing Partner of HRZN Partners LLC and a Senior Advisor to Amgen. Most recently, he was Chairman, President, and Chief Executive Officer of Horizon Therapeutics, which he grew to approximately $4 billion in annual sales prior to its $28.3 billion acquisition by Amgen in 2023; earlier, he led IDM Pharma Inc. through its acquisition by Takeda and held senior roles at Abbott (now AbbVie), where he led the global launch of HUMIRA®, as well as at G.D. Searle & Company, Merck & Co., and Wyeth.
“Patient Square Capital has built a highly differentiated platform and a strong record of partnering with management teams to create enduring value in health care,” said Tim Walbert. “I'm pleased to join the firm as a Senior ...
|
|
|
05.05.26 - 15:03
|
Zifo′s SiEE Boston Summit Charts New Roadmap for ′Practical AI′ in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality (PR Newswire)
|
|
|
BOSTON, May 5, 2026 /PRNewswire/ -- Trading the abstract allure of AI hype for a technical implementation roadmap, Zifo's 2026 Scientific Informatics Experience Exchange (SiEE) in Boston concluded with heavyweights from Sanofi, Takeda, AbbVie, Regeneron, Biogen, Eli Lilly, Novo Nordisk,......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.04.26 - 16:42
|
Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy (24/7 Wall St.)
|
|
|
Our AbbVie (NYSE:ABBV) call lands on the constructive side of the ledger after a noisy but encouraging Q1 earnings report. The 24/7 Wall St. price target for AbbVie is $229.32, implying 12.47% upside from the recent close of $203.89. We rate ABBV a buy with high confidence (90%), driven by Skyrizi and Rinvoq momentum, raised ... Price Prediction: Why AbbVie's Post-Humira Pivot Makes It a Strong Buy...
|
|
|
|
|
30.04.26 - 13:54
|
Here Are Thursday′s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More (24/7 Wall St.)
|
|
|
Pre-Market Stock Futures: Futures are trading higher this morning after a messy Wednesday trading session that saw all major indices except the Nasdaq end lower, with the Nasdaq closing virtually unchanged at 24,603, up 0.04%. The combination of soaring oil prices, the Federal Reserve keeping interest rates unchanged for the third straight meeting, and bogged-down ... Here Are Thursday's Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More...
|
|
|
30.04.26 - 02:24
|
AbbVie′s patent on immunology therapy rejected (Times of India)
|
|
|
Good news for Indian patients as the Patent Office rejected AbbVie's Rinvoq patent, citing obviousness and lack of inventive step. This decision, crucial for affordable generic versions, prevents patent 'evergreening' and upholds India's patent law. Generic manufacturers had opposed the application, leading to extensive hearings. Rinvoq treats autoimmune diseases and has significant global sales....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
